Founded in 2008, BrioHealth Technologies is dedicated to the development, manufacturing, and commercialization of breakthrough ventricular assist devices (VADs)—commonly known as artificial hearts. Through continuous innovation and clinical collaboration, the company advances global standards in circulatory support and helps patients with heart failure regain healthy, fulfilling lives.

The BrioVAD system represents a new generation of ultra-compact, fully magnetically levitated implantable heart pumps. Engineered for superior hemocompatibility, reduced infection risk, and enhanced reliability, it integrates pioneering technologies in magnetic levitation, fluid dynamics, and percutaneous driveline design—setting new benchmarks in long-term cardiac support performance.

BrioHealth operates under a comprehensive quality management system aligned with ISO 13485 and FDA standards, covering the full product lifecycle from design to post-market service. Holding patents across the U.S., Europe, China and Japan, the company is building a global foundation for commercialization. In 2024, BrioVAD received FDA Investigational Device Exemption (IDE) approval and began clinical trials in the United States—a milestone that underscores BrioHealth’s leadership in advancing next-generation implantable medical devices worldwide.

Driven by innovation and compassion, BrioHealth continues to collaborate with clinicians and institutions globally to redefine the future of heart-failure therapy.

BrioHealth Technologies

Org chart

Teams

Offices